{
    "nct_id": "NCT06233591",
    "official_title": "A Multicenter, Dose-Ranging Trial Evaluating the Safety, Tolerability, and Efficacy of LP-10 in Subjects With Symptomatic Oral Lichen Planus",
    "inclusion_criteria": "* Provide written informed consent\n* Male or female ≥ 18 years of age\n* Oral biopsy performed within the last 10 years before the Screening Visit demonstrating OLP and/or oral lichenoid mucositis in the absence of cancer or dysplasia\n* Moderate OLP based on an OLP Investigator Global Assessment (IGA) score of ≥ 3\n* OLP Pain and Sensitivity Numerical Rating Scale (NRS) score of ≥ 3\n* Patients taking prescription oral steroid or rinse treatment(s) at the time of the Screening Visit agree to stop treatment for the duration of the trial and to undergo a 4-week washout period\n* Willing and capable of understanding and complying with all requirements of the protocol, including proper completion of the self-administered questionnaires\n* Willing to avoid live vaccines while enrolled in the trial\n* Patients of child-bearing potential must have a negative pregnancy test and agree to undergo pregnancy testing at each study visit. (unless patient has undergone a bilateral tubal ligation or hysterectomy and/or is post-menopausal as defined by the absence of menses for at least 12 months)\n* Patients of child-bearing potential and male participants with a female partner of child-bearing potential, agree to use a reliable method of contraception (condoms and/or oral contraceptives) for the duration of the trial and for 10 days thereafter\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Hyperkalemia\n* Chronic kidney disease\n* Long QT syndrome\n* History of oral cavity or oropharyngeal cancers\n* Active cancer\n* Uncontrolled hypertension (i.e., > 145 mm/Hg systolic or > 95 mmHg diastolic)\n* Patients who failed tacrolimus treatment for OLP in the past\n* Patient who is currently or has previously participated in another oral cavity therapeutic or device study within 3 months of screening and has not returned to baseline\n* History of oral cavity infection (bacterial, viral or fungal) within 3 months prior to screening\n* Pregnant or lactating\n* Active bleeding peptic ulcer disease\n* Known allergy to liposomes and/or egg yolk and/or tacrolimus\n* Evidence of renal impairment (creatinine > 2 × the upper limit of normal at Visit 1), hepatic impairment (AST or ALT > 3 × the upper limit of normal at Visit 1), clinically significant cardiovascular, respiratory, or psychiatric diseases per investigator's judgment\n* Patients currently taking magnesium and aluminum-hydroxide antacids or metoclopramide\n* Patients currently taking aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, and protease inhibitors\n* The presence of any clinically significant systemic disease or condition that in the opinion of the investigator would make the patient unsuitable for the study",
    "miscellaneous_criteria": ""
}